Cambrex has recorded a gain in the second quarter of this year,
with growth in its Bioproducts and Human Health segments. The
performances overshadow the company's troublesome BioPharma
division, indicative of a market for outsourced...
Swiss chemicals firm and contract manufacturer Lonza fulfilled its
promise of stronger financial results in the first half of 2005,
with profits coming in at the lower end of the forecast range, but
still on target, reports Phil Taylor.
A recent study designed to assess biopharmaceutical innovation in
the member states of the Organisation for Economic Cooperation and
Development has found that, in terms of innovation and
biotechnology industry development, Belgium...
Hamilton launches two new products, which are set to aid the
facilitation of automation in laboratories, placing tedious and
time-consuming processes in the hands of cutting edge and
cost-effective technology for automation.
US scientists have shown that microRNA (miRNA) plays an essential
role in the development of the fruit fly. The discovery means that
miRNA could emerge as a new target for interventions aimed at
treating disease, or as a therapeutic...
Lonza has started a SF 14 million (€9m) expansion of its biologics
manufacturing facility in Slough, UK, in response to what it said
was increasing demand for mammalian cell production for clinical
trials, reports Phil Taylor.
Dynal Biotech has announced two product releases from its new
proteomic preparation range, which use magnetic bead chromatography
technology to prepare for mass spectrum analysis without the
requirement of columns.
The use of DNA as a vaccine has been an exciting but elusive
prospect in drug development for many years, held back by problems
with effectivness and difficulties in production. But this could be
about to change, reports Phil Taylor.
According to a recent report, the global bioinformatics market is
currently estimated at about $1.4 billion (€1.1 billion). It is
expected to grow at an average annual growth rate of 15.8 per cent
to reach nearly $3 billion by 2010,...
BioProgress has appointed Richard Trevillion as chief
executive, bolstering its executive management just over a month
after the dosage film specialist issued a trading statement that
sparked a 40 per cent slump in its UK-listed shares,...
Biosample management firm, GenVault announced an exclusive
agreement to acquire the full rights to a DNA labelling
intellectual property, which allows researchers to identify the
sample through its complete downstream analysis to...